Skip to main content
. 2021 Oct 7;44(12):1341–1353. doi: 10.1007/s40264-021-01118-3

Fig. 2.

Fig. 2

Significance area for the equality test of observed and expected incidences of herpes zoster within 30 days (day 0–29) after vaccination with the adjuvanted recombinant zoster vaccine in a Canada, b Germany, c the USA, and d worldwide. Number of doses distributed was 2,170,178 for Canada, 1,045,785 for Germany, 29,380,658 for the USA, and 32,597,779 worldwide. Background incidence represents the herpes zoster incidence rate in the general population and is adjusted for the age distribution of recipients of the adjuvanted recombinant zoster vaccine. CI confidence interval